MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alpha Cognition Inc.

< Previous 1 2 Next >
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Provides Business Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Launches $6.5 Million Private Placement
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX:ACOG
Alpha Cognition Provides Private Placement Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Grant of Stock Options
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces First Quarter 2022 Results and Company Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Fourth Quarter and Full Year 2021 Results and Company Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of Directors
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Positive Data from Pre-Clinical Studies of ALPHA-0602 (Progranulin) for Amyotrophic Lateral Sclerosis (ALS)
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF
Alpha Cognition Announces Positive Neuroprotection Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF
Alpha Cognition Announces Participation in January Investor Conferences
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF
Alpha Cognition Announces Director Change and Stock Option Grant
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF
Alpha Cognition Announce Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF
Alpha Cognition Appoints Cedric O’Gorman, M.D., MBA as Chief Medical Officer
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF
Alpha Cognition Reports Third Quarter of Fiscal 2021 Results
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF
Alpha Cognition to Present at LD Micro Main Event
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story